Aflac Supplemental Insurance and Japan Market Study

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it enlarging an existing pie, or creating an entirely new market?5/10

  A

  Conclusion: Aflac is "enlarging and defending a slice of an existing, mature pie," not creating an entirely new market. Its ceiling is set by Japan's aging-driven out-of-pocket medical gap and the penetration rate of the U.S. high-deductible medical system—a stable but not steep long runway, far from the "exponential new category" Baillie Gifford favors.

  First, the nature of the pie. Supplemental health insurance (cancer, medical, accident, and critical-illness coverage) is a mature category that has existed for decades, with clear demand logic but well-defined boundaries: in Japan it rests on an aging population plus rising out-of-pocket pressure under public health insurance, and in the U.S. on consumers' out-of-pocket burden under high-deductible plans. The report sets industry attractiveness at 3/5 and states clearly that it is "not a perfect industry, but one with stable long-term demand where good discipline earns decent money," a far cry from the "entirely new market" Baillie Gifford seeks.

  Next, Aflac's position within the pie: it has long been the leader, meaning the room to "enlarge the existing pie" comes mainly from penetrating the installed base rather than opening new frontiers. The report notes that Aflac Japan "pioneered the cancer-insurance market in Japan in 1974 and remains the largest cancer-insurance provider in Japan to this day"; by the company's 2025 Business and Sustainability Report, Aflac Japan holds over 22 million individual policies, of which about 14 million are cancer policies, making it the leader by policy count in cancer and medical insurance in Japan. For a player already sitting in the top seat, the ceiling is set more by "how large this pie itself can grow" than by "whether it can build another pie."

  Can the pie be "enlarged" through innovation? A little, but as mild expansion rather than the creation of a new market. In 2025 Aflac Japan grew full-year sales about 16% on the back of Miraito, a new cancer product launched in March, showing that product iteration can lift demand within an existing category in phases—but this is new wine in a new bottle within the old "cancer insurance" category, not the opening of a coverage line that did not exist before. The U.S. is the same: the report describes its products as "mainly supplemental coverage for people who already have basic medical insurance," essentially widening penetration in the gaps of the existing medical system.

  The real constraint on the ceiling is that this category is inherently a "mature industry" rather than an "emerging market." The report repeatedly stresses that Aflac is "a good company in a mature industry, not an explosive company in a high-growth industry," with organic growth in the "low-to-mid single digits." In other words, even treating both Japan's and the U.S.'s out-of-pocket gaps as a long runway, the slope of that runway is capped at the top by demographics and regulated pricing—it will not see the zero-to-one demand burst of a category just created by technology.

  In one line: measured by Baillie Gifford's yardstick of "enlarging an existing pie vs. creating a new market," Aflac falls clearly into the former, and it is the player that has already taken the largest slice. This makes its story one of "steady-state compounding," not a "growth myth with an ever-rising ceiling."

  Jun 11, 2026
• QCan its revenue at least double over the next five years? Is growth driven mainly by volume, price, or new businesses?3/10

  A

  Conclusion: almost impossible. Doubling Aflac's revenue over the next five years (about 15% annualized) sharply contradicts its actual growth curve—this is a mature insurer with low-to-mid single-digit organic growth whose revenue has in fact declined in recent years; "doubling" has neither a volume engine, nor price elasticity, nor new businesses of sufficient scale to support it.

  First, puncture the possibility of doubling with facts. Baillie Gifford's LTGG core threshold is "revenue doubling in five years," corresponding to about 15% CAGR. Aflac's reality runs the opposite way: the report shows GAAP total revenue declining all the way from $21.554 billion in 2021 to $17.164 billion in 2025, with about $4.346 billion in Q1 2025 alone. Even stripping out FX and investment-accounting noise and using the smoother adjusted measure, adjusted diluted EPS only rose from $5.80 in 2021 to $7.49 in 2025 (the company's Q4 2025 earnings release confirmed full-year adjusted earnings of $4 billion, or $7.49/share), a four-year CAGR of about 6.6%. For a business that runs at single digits over the long run and whose top line is still shrinking, five-year doubling has no data basis whatsoever.

  Breaking down the three engines—volume, price, new business—one by one, none is strong enough:

  Volume: Japan is the core but already the leader, so penetration expansion is gradual. Aflac Japan grew full-year sales about 16% in 2025, driven mainly by the March new product Miraito—a rare good year, but sales (new-policy) growth does not equal a doubling of premium income, and the rollover of the in-force book is the bulk of revenue. The report specifically flags that Japan's premium side "is still pressured by limited-pay products converting to paid-up status and by reinsurance transactions," meaning many policies stop contributing new premiums once their paying period ends, which will keep dragging on top-line volume. On the U.S. side, Q1 2026 net earned premiums grew only single digits year over year.

  Price: pricing power is doubly constrained by regulation and competition. The report explicitly rates "does it have pricing power" as "uncertain," on the grounds that it has "some product and channel pricing ability, but constrained by regulation and competition." Supplemental-insurance rates must pass regulators and be benchmarked against peers, so there is no room to double revenue through price hikes.

  New business: too small to support a doubling. In recent years Aflac's capital has gone almost entirely to buybacks and dividends (see below) rather than incubating a new growth pole that could recreate an Aflac; in its "second curve" assessment, the report identifies no new business anywhere near the scale of the core.

  Currency will also erode dollar-reported revenue in the opposite direction. About 53% of Aflac's adjusted revenue comes from Japan and is denominated in yen; if the yen weakens, consolidated revenue translated into dollars is pushed down further—exactly the opposite of "doubling."

  One point to make explicit: Aflac's real path to lifting "per-share" value is shrinking the share count, rather than growing revenue. The company repurchased about $3.5 billion in 2025 and another $1 billion in Q1 2026, with shares outstanding down about 7.2% over 15 months. This lets EPS run faster than revenue, but it precisely shows that this company's growth narrative is "denominator shrinking" rather than "numerator doubling."

  In one line: holding Baillie Gifford's hard yardstick of "five-year revenue doubling" against Aflac, the answer is a clear "no"—it is a mature cash cow that makes money on renewal steady-state and buyback compounding, not a growth stock whose top line can double.

  Jun 11, 2026
• QFive years from now, what will take over as the next growth engine? Does this "second curve" exist today?4/10

  A

  Conclusion: no "second curve" of meaningful scale is visible today. Aflac's baton-holder five years out will most likely still be an extension of the same set of engines—installed-base penetration in Japan's third-sector insurance, gradual expansion of U.S. supplemental insurance, plus investment income and share-count reduction—rather than an independent new growth pole. To Baillie Gifford's question of "does the second curve already exist today," the honest answer is: no new curve capable of recreating an Aflac has yet grown out.

  Define the main curve first, then judge the "baton" gap. Aflac's profit today is highly concentrated in Japan: the report shows the Japan business accounted for about 53% of total adjusted revenue in 2025 and, by segment data, about 69% of pretax adjusted profit, with Aflac Japan's 2025 pretax adjusted profit at $3.440 billion and a 36.7% margin; by Q1 2026, the Japan segment's pretax adjusted profit was $759 million with a 35.0% margin (the company's Q1 2026 earnings release; 31.8% a year earlier). This is a mature, stable but modestly growing engine. The question is: five years out, who takes over the increment of this engine?

  Candidate one: U.S. supplemental insurance—an extension rather than a new curve, and more fiercely competitive. The U.S. segment's 2025 pretax adjusted margin was about 20.6%, and Q1 2026 was 20.4%, clearly below Japan, and the report states bluntly that the U.S. market is "more fragmented, with stronger price and channel competition," while the company itself admits large medical insurers could invade supplemental insurance through bundling and discounting. It can contribute steady cash flow, but it is hard-pressed to become a second curve that lifts the overall growth rate to a new level.

  Candidate two: Japanese product iteration (such as Miraito)—it can extend the main curve, but stays within the old category. Aflac Japan grew full-year sales about 16% in 2025 on the March new product, showing that product innovation can prolong the main curve in phases, but this is a generational refresh within the existing cancer/medical category, not the opening of a new coverage line or a new major revenue class.

  Candidate three: investment income + share-count reduction—"financial leverage" rather than a "business second curve." The report clearly points the source of per-share value growth to buybacks: about $3.5 billion repurchased in 2025 and another $1 billion in Q1 2026, with shares outstanding down about 7.2% over 15 months. This can keep EPS moving up, but it splits the same profit among fewer shares and is not a new business at heart. The report also specifically cautions that when the share price is already not cheap (currently about $117, nearing the 52-week high of $119.81), "the marginal benefit of buybacks is declining"—meaning the future accretion efficiency of this "financial curve" is itself being discounted.

  Hold up Baillie Gifford's yardstick: the "second curve" it wants is a brand-new business line already sprouting today that can independently carry growth in the future. Aflac has nothing of the sort—its future is "the same set of engines running more efficiently + the denominator shrinking," a continuation of steady-state compounding, not the opening of a new story. The report's overall judgment (a good company in a mature industry, low-to-mid single-digit organic growth, "Watch" rating) is fully consistent with this.

  In one line: Aflac's "baton-holder" five years out is most likely still itself—Japan franchise + U.S. cash cow + buybacks—and what it lacks is precisely the independent second curve Baillie Gifford values most. For a mature cash cow this is not a flaw, but within the growth-investing paradigm it is exactly where its ceiling lies.

  Jun 11, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?6/10

  A

  Conclusion: Aflac's core moat is a trinity of "brand + cross-channel distribution + scale cost" in Japan's third-sector insurance—real and fairly deep; but through Baillie Gifford's forward-looking lens of "widen or narrow over the next three to five years," it is more likely to run from stable to "marginally narrower"—it is a high-quality levee, not a flywheel that keeps building higher. The report gives the moat 4/5, and I agree this is a moat that is "established but no longer thickening."

  First, clarify what the moat is and where its strength lies. It rests on several old-school but real barriers, rather than network effects or patents. The most valuable piece is in Japan: the report notes that Aflac Japan "pioneered the cancer-insurance market in Japan in 1974 and remains the largest cancer-insurance provider in Japan to this day," and by the company's 2025 Business and Sustainability Report, Aflac Japan holds over 22 million individual policies and about 14 million cancer policies. Distribution is the part hardest for latecomers to replicate—the report shows the Japan business simultaneously covers about 6,300 sales agencies and about 112,000 licensed sales representatives, with about 37,000 representatives covered through the Dai-ichi Life partnership, about 20,000 post-office locations through the Japan Post Group partnership, and sales agreements with about 90% of Japan's banks. The brand (Aflac Duck), the low-cost operations that scale brings, and regulatory entry friction together form this moat.

  The moat's "reality" has financial corroboration. The report shows Aflac Japan's trailing 12-month premium persistency in Q1 2026 was as high as 92.8%, and this stickiness is exactly the retention that brand + channels convert into; the Japan segment margin of 35.0% (the company's Q1 2026 release) also shows the barrier has indeed converted into pricing and profit, not a paper narrative. This makes it stronger than story stocks that "have a moat but do not make money."

  But looking forward, the direction of this moat is "stable to marginally shrinking" rather than widening, for three reasons:

  First, the Japanese market was deregulated long ago and competition is intensifying. The report states clearly that "since Japan deregulated its market in 2001, independent cancer- and medical-insurance providers have proliferated and competition has intensified"—in a market already opened up, first-mover exclusivity is diluted by time rather than self-reinforcing.

  Second, the U.S. barrier is inherently shallower and faces a bundling threat. The report judges the "U.S. barrier to be weaker" and cites the company's own admission in the 10-K: larger medical insurers could use core benefit products for bundling and discounting to fight for supplemental-insurance share. Supplemental insurance is not an exclusive category, and its moat relies more on channel touchpoints than on irreplaceability.

  Third, it has no "gets stronger with use" flywheel mechanism. The report puts it bluntly: Aflac "has no tech-platform flywheel," its moat "is sustainable, but not untouchable," and overall "has not clearly widened, but has not clearly narrowed to a dangerous degree either." The absence of a self-reinforcing mechanism means its best case is holding ground, not widening.

  Real narrowing signals to watch (the report lists them as overturning conditions, usable as tracking anchors): Japan's trailing 12-month premium persistency clearly falling below the low-90% range, Japan's pretax margin falling significantly below 30%, or adjusted ROE excluding currency remeasurement dropping below 13% over the long run—any one of these means the levee is being eroded. The current 16.4% Q1 2026 adjusted ROE excluding currency remeasurement is still some distance from these warning lines, so the moat remains solid for now.

  In one line: this is a real, verifiable moat that is still solid today, but it is the "can-hold-its-ground" type rather than the "keeps-building-higher" type. By Baillie Gifford's three-to-five-year forward yardstick, the direction is flat to marginally shrinking—exactly why Aflac earns "high quality" but not a "growth myth."

  Jun 11, 2026
• QIf its core business were disrupted, does it have the DNA to reinvent itself? How does it treat mistakes and bad news?4/10

  A

  Conclusion: Aflac treats mistakes and bad news with an attitude of "transparent, steady, and willing to own up"—a plus for governance; but asked whether it has "the reinvention DNA to tear things down and start over when the core business is disrupted," the answer leans weak: it is a disciplined mature insurer that wins on steady-state operations and capital management, and at its core it is not the kind of company that can quickly transform and be reborn when its main business is disrupted. These two things must be viewed separately.

  First, "how it treats mistakes and bad news"—this side is quite steady. The most direct example is the June 2025 U.S. cybersecurity incident: the company did not dodge it but disclosed publicly and kept updating, and per Aflac's official update of December 19, 2025 it proactively explained that the incident involved the personal information of about 22.65 million people, that the investigation had been completed, and that it had begun notifying affected individuals and offering credit monitoring and identity-theft protection. The report calls this a plus, in that it "did not pretend nothing had happened when it came to transparency." It is equally candid on accounting: the report notes KPMG gave an unqualified opinion on the 2025 statements and internal controls, while listing "private-placement bond fair-value valuation" and "valuation of the liability for future policy benefits" as critical audit matters—putting the two most subjective, most problem-prone areas on the table rather than hiding them. This shows that when facing bad news, the company chooses disclosure and management rather than whitewashing.

  But "candidly owning up" does not equal "reinvention DNA," and the latter is the harder half of this question. Baillie Gifford asks: when the core business (Japan's third-sector insurance) is disrupted by some force, does this company have the ability, like a great growth stock, to tear down its main business and grow a new form? On the evidence, Aflac's DNA is the opposite—all of its advantages are built on "staying unchanged":

  First, the management structure is highly stable and conservative. The report shows Daniel P. Amos has been CEO since 1990 and chairman since 2001, an extremely long tenure. A long tenure brings strategic coherence and cultural stability, but it also means this is a team good at guarding the existing franchise rather than disrupting itself; the report also flags management succession itself as a variable that must be watched going forward.

  Second, the capital-allocation path is "returning capital to shareholders" rather than "rebuilding the business." In recent years the company's capital has gone almost entirely to buybacks and dividends—about $3.5 billion repurchased in 2025 and another $1 billion in Q1 2026—and the report explicitly praises it for "not squandering capital on large, high-priced acquisitions." This is a virtue for a mature insurer, but it also means the company is not using real money to incubate a "backup for when the main business is disrupted," lacking the investment that reinvention requires.

  Third, the moat itself is the "defend" type rather than the "transform" type. The report notes Aflac "has no tech-platform flywheel" and that the moat "is sustainable, but not untouchable." A business that wins on brand accumulation, channel touchpoints, and scale cost has its strength in weathering storms, not in changing its hull shape amid the storm.

  Fortunately, its probability of being disrupted is inherently low, which partly hedges the worry about "weak reinvention DNA." The report judges that supplemental insurance "is not especially easy to disrupt overnight through technology," and the real disruptive variables are gradual forces such as regulation, channels, product design, and competitor bundling—giving the company a time window to respond gradually through steady operations, without needing to revolutionize itself overnight.

  In one line: Aflac is a company that "owns up, discloses, and handles bad news soundly when it comes," and its governance is credible; but its DNA is guarding rather than reinventing—not much of a problem in its mature industry that is hard to disrupt overnight, yet exactly where it falls short of Baillie Gifford's standard of a "great growth stock that can rise from the ashes amid disruption."

  Jun 11, 2026
• QDoes management (especially the founder) have a long-term horizon, with interests deeply aligned with the company? Is it willing to sacrifice current profit for five to ten years out?5/10

  A

  Conclusion: management does have a long-term horizon and good capital discipline, but the degree of "deep alignment with the company" is only moderate—this is not the strong alignment of a founder with a heavy stake whose fate runs along the same line as shareholders'; and the Baillie Gifford-style trait of "willing to sacrifice current profit for five to ten years out" is essentially absent at Aflac—its orientation is precisely to steadily reward current shareholders (dividends + buybacks) rather than to sacrifice the present for a long-term bet.

  First, the long-term horizon and stability—this side holds. The report shows Daniel P. Amos has been CEO since 1990 and chairman since 2001, a very long tenure, bringing strategic coherence and cultural stability. Capital discipline is indeed excellent: the company has long avoided large, high-priced acquisitions, instead paying continuous dividends and buybacks, and the report specifically records that in Q1 2026 management said it values its "43-year record of dividend growth" and kept the Q1 2026 quarterly dividend at $0.61 (declared per the company's Q4 2025 release). This is a management team that knows "where the cash ultimately goes."

  But measured by Baillie Gifford's "deep alignment" yardstick, it only reaches moderate, and the key is shareholding. The report cites the Proxy: CEO Amos directly and indirectly holds about 2.905 million shares, roughly 0.6% of shares outstanding; all directors, nominees, and executives together hold about 4.327 million shares, roughly 0.8%. This is clearly far from the founder-led companies with double-digit founder stakes that Baillie Gifford favors. The company does have ownership requirements (the CEO must hold stock worth 8x base salary), and on that basis the report judges that "there is alignment of interests, but not the kind of extreme, strong alignment where management is tied to the same line of fate as you." In other words, incentive alignment relies on institutional requirements rather than a natural sharing of risk through a large own-capital stake.

  Now the point Baillie Gifford values most—"willing to sacrifice current profit for five to ten years out"—Aflac's answer is "essentially no, and its virtues are built precisely on the opposite orientation":

  First, capital goes almost entirely to rewarding current shareholders rather than investing for the long term. About $3.5 billion repurchased in 2025, another $1 billion in Q1 2026 plus $315 million in dividends, with shares outstanding down about 7.2% over 15 months. This is the approach of returning profit to shareholders as fast as possible, a philosophy entirely different from "holding down current profit and pouring money into a new curve ten years out."

  Second, the commitment of 43 consecutive years of dividend increases is itself a "present-first" constraint. To protect that record, management must keep distributing cash, which further limits its room and willingness to sacrifice near-term profit heavily for the long term.

  Third, the report also notes that the flaw in capital allocation lies in "timing" rather than "direction"—continuing large buybacks at a high level, currently about $117, nearing the 52-week high of $119.81, lowers the accretion efficiency per $1 of buyback. This precisely shows that management's default action is "keep buying back in the present," rather than "preserving ammunition for better long-term opportunities." On that basis the report rates management and capital allocation 4/5 rather than full marks.

  To be fair: for a mature insurer, "not sacrificing current profit for a nebulous long term" is precisely a virtue, a discipline responsible to shareholders. The only issue is that this is a different evaluation system from Baillie Gifford's search for "growth-oriented management willing to endure near-term profit declines for five to ten years out." By Baillie Gifford's yardstick, Aflac's management is "credible but not aggressive, moderately aligned, and present-leaning in orientation."

  In one line: trustworthy, well-disciplined, with a long enough horizon—but a management team of moderate alignment that at its core is "rewarding the present" rather than "betting on the long term." This is a plus for a mature cash cow, but within the growth-investing paradigm it is where it falls short of top marks.

  Jun 11, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and not reliant on harming society or regulation?6/10

  A

  Conclusion: view it on two levels. "Indispensability"—moderately strong in Japan, weak in the U.S.: if Aflac disappeared tomorrow, the tens of millions of Japanese cancer/medical policyholders would genuinely miss it (hard to replace, deeply embedded brand), but U.S. customers are more easily replaced by comparable supplemental insurance. "Growth sustainability"—very high and with no social/regulatory antagonist: it makes its money cleanly, by helping people share out-of-pocket medical costs rather than harming society or crossing regulatory red lines. Both levels hold, but the "indispensability" item is dragged down by the Japan-U.S. difference.

  First, indispensability—this is the essence of Baillie Gifford's "how much would customers miss it." On the Japan side the answer leans strong. The report notes that Aflac Japan "pioneered the cancer-insurance market in Japan in 1974 and remains the largest cancer-insurance provider in Japan to this day," and by the company's 2025 Business and Sustainability Report it holds about 14 million cancer policies. The more crucial evidence is stickiness: the report shows Aflac Japan's trailing 12-month premium persistency in Q1 2026 was as high as 92.8%—meaning policyholders rarely leave voluntarily, which is itself a quantification of "how much it is missed." For a Japanese family that has cancer or fears it, this policy is tied to hard-cash benefits, not an optional consumer good.

  But on the U.S. side, indispensability is clearly weaker. The report judges the U.S. market to be "more fragmented, with stronger price and channel competition," and the U.S. trailing 12-month premium persistency is only 79.3% (far below Japan's 92.8%), showing that U.S. customer retention is far less sticky. The company itself admits in the 10-K that larger medical insurers could fight for supplemental-insurance share through bundling and discounting—in other words, if U.S. customers lost Aflac, replacements would not be hard to find in the market. So on the question of "how much it would be missed if it disappeared tomorrow," Japan is "greatly missed" and the U.S. is "missed, but replaceable."

  Now the second level—whether the growth model is sustainable and whether it relies on harming society and regulation—on this item Aflac answers quite cleanly.

  First, the business itself has positive social value and is neither zero-sum nor predatory. The report describes its products as "supplemental coverage for people who already have basic medical insurance," paying cash-type benefits when customers experience events such as cancer, hospitalization, accidents, critical illness, and long-term care. Japan's aging and out-of-pocket medical pressure, and the out-of-pocket burden under the U.S. high-deductible system, are the true sources of its long-term demand—it helps people share medical financial risks that already exist, rather than manufacturing problems and then charging for them.

  Second, it operates within the regulatory framework, and regulation is its moat rather than its antagonist. The report repeatedly stresses that supplemental insurance is a "mature and heavily regulated industry," and the company operates under constraints such as Japan's SMR / economic-value capital rules and U.S. RBC. Its growth depends on complying with regulation and passing rate approvals, not on evading regulation or profiting by harming consumers—entirely different from businesses where "the faster the growth, the greater the social cost."

  Third, the only "social-side flaw" is data security, rather than the business model itself. The June 2025 U.S. cybersecurity incident involved the personal information of about 22.65 million people (confirmed by the company's official update)—a real operating risk and real harm to customers that must be taken seriously; but it is an execution-level lapse, not a structural problem of "growing by harming users," and the company has publicly disclosed it and provided remediation.

  Putting Baillie Gifford's yardstick together: Aflac passes the "sustainable growth model, not at odds with society and regulation" test with a high, clean score; but the "indispensable enough that customers cannot leave" test is only a partial pass—strong in Japan, weak in the U.S. This is fully consistent with the report's overall judgment that "Japan is the high-quality engine and the U.S. is the more competitive supporting cash cow."

  In one line: the money is earned cleanly and the long runway is sustainable, but "irreplaceable" holds only in Japan and is discounted in the U.S.—it would be missed by many, though it is not the kind of business that everyone cannot live without.

  Jun 11, 2026
• QWhat are this business's unit economics (gross margin, incremental returns)? Do they get better or worse as it scales? Where does the money it earns go?6/10

  A

  Conclusion: Aflac's unit economics are high-quality within the insurance industry—the Japan segment's pretax margin is about 35% and the U.S. about 20%, assets are extremely light, and incremental capital hardly needs to be reinvested in plants; but as it scales it "will not keep getting better," because it is already the leader and its incremental growth comes mainly from gradual penetration of mature markets, rather than a flywheel of declining marginal cost. The vast majority of the money it earns goes to buybacks and dividends, rather than to new growth that could amplify unit economics. Three things must be addressed separately.

  First, the unit economics themselves—genuinely high-quality. Insurers have no traditional gross margin, and the closest measure is segment pretax adjusted margin. The report shows Aflac Japan's 2025 pretax adjusted margin at 36.7% and Aflac U.S. at 20.6%; by Q1 2026, Japan was 35.0% and the U.S. 20.4% (both on the company's Q1 2026 earnings-release basis, with Japan improved year over year from 31.8%). This "Japan engine's" margin would be top-tier in any industry. The asset burden is also extremely light—the report notes 2025 depreciation and other amortization of only $36 million and property and equipment of only $351 million, meaning maintenance capex is almost negligible and every extra dollar earned need not first be plowed back into fixed assets. The true measure of incremental return is ROE: the report shows adjusted ROE excluding currency remeasurement held at 14.9%–17.6% in 2021–2025 and still 16.4% in Q1 2026, a steady, high mid-teens return.

  Now what Baillie Gifford really asks—"do unit economics get better or worse as it scales"—Aflac's answer leans toward "flat, no longer rising," which is the watershed between it and a growth stock:

  First, it is already the leader, and the scale dividend is largely cashed out. The report notes Aflac Japan has long been No. 1 by cancer and medical policy count in Japan, with about 14 million cancer policies. Scale effects (low-cost operations, brand amortization, channel density) are the source of its high margins today, but these dividends are already reflected in the current margins, and growing further will not significantly lower marginal cost—it has no software-style incremental flywheel of "nearly zero cost for one more user."

  Second, incremental growth comes from gradual penetration of mature markets, accompanied by competitive pressure. The report flags that Japan's premium side is pressured by limited-pay products converting to paid-up status and by reinsurance transactions, and that the U.S. side is "more fragmented, with stronger price and channel competition" and faces bundling by large medical insurers. Growing in such an environment is more likely to see marginal unit economics ground down by competition than to see them self-reinforce. On that basis the report sets industry attractiveness at 3/5 and the business overall as "a good company in a mature industry."

  Third, the mixed-business structure means "growing" does not necessarily improve the overall margin. The U.S. segment margin (about 20%) is only a bit more than half of Japan's (about 35%), and if future incremental growth comes more from the more competitive, thinner-margin U.S. side, overall unit economics could even be structurally diluted rather than improved.

  Finally, "where the money it earns goes"—this is the key to whether unit economics translate into shareholder value, and Aflac's answer is "almost all returned to shareholders": about $3.5 billion repurchased in 2025 with the full-year dividend raised to $0.61/quarter; another $1 billion repurchased in Q1 2026 plus $315 million in dividends, with shares outstanding down about 7.2% over 15 months. The virtue is that it does not waste cash on value-destructive acquisitions; but the crux is here too—this money goes to "shrinking the denominator" rather than "investing in new businesses that could amplify unit economics." The report also cautions that continuing buybacks at a high level, currently about $117, nearing the 52-week high of $119.81, means the accretion efficiency per $1 is already declining.

  In one line: unit economics are high-quality (high margins, light assets, steady ROE), but already in the mature state of "scale dividend cashed out, no longer rising"; the cash earned is cleanly returned to shareholders, but not reinvested to amplify unit economics—exactly the core numerical evidence for why it earns "good business" but not "accelerating growth."

  Jun 11, 2026
• QFor it to rise fivefold in ten years, what conditions must hold simultaneously? Are these conditions realistic? What expectations does today's share price imply?2/10

  A

  Conclusion: Aflac rising fivefold in ten years (let alone the "ten-bagger in ten years" Baillie Gifford habitually talks about) is nearly unrealistic—given its single-digit organic growth and the valuation ceiling of a mature insurance stock, a fivefold gain would require a set of mutually contradictory, mostly untenable conditions to occur at once. The expectations implied by today's roughly $117 price are instead quite modest: the market has already priced it as a "fair-to-slightly-expensive mature cash cow," granting no discount for explosive growth, which is exactly the root of the capped upside.

  First, translate "fivefold in ten years" into hard conditions. Fivefold corresponds to about 17.5% annualized total return, sustained for ten years. For a mature insurance stock, this can only come from both legs firing hard at once: rapid growth in per-share intrinsic value (earnings/book) + a large expansion of the valuation multiple. Checking one by one, none holds up:

  Condition one: EPS must grow rapidly year after year—unrealistic. The report shows adjusted diluted EPS going from $5.80 in 2021 to $7.49 in 2025 (the company's Q4 2025 release), a four-year CAGR of only about 6.6%; adjusted book value excluding currency remeasurement rose only from $37.71/share to $42.66/share in 2021–2025, about 3.1% compounded. The report states clearly that this is a company of "low-to-mid single-digit organic growth." A single-digit base supporting a 17.5% annualized return leaves too large a gap.

  Condition two: the valuation multiple must rise sharply again from "fair-to-slightly-expensive"—the opposite of reality. The report calculates the current price at about 15.7x adjusted EPS and about 2.14x adjusted book value, already in a historically not-cheap zone. Mature insurance stocks have a multiple ceiling, and the report even flags that in a downside scenario the market could re-price at 1.3–1.5x adjusted book or 10–12x adjusted EPS. The multiple is more likely to compress than to expand doubly.

  Condition three: buybacks must accrete efficiently over the long run—but efficiency is declining. Buybacks can indeed make EPS outpace revenue (shares outstanding down about 7.2% over 15 months), but the report notes that buying back at a high level, currently about $117, nearing the 52-week high of $119.81, lowers the accretion efficiency per $1. Share-count reduction can contribute mid-single-digit per-share accretion at most, far from enough to add up to fivefold.

  Condition four: Japan and currency must both provide tailwinds over the long run—uncertain and partly a headwind. Japan contributes about 53% of adjusted revenue and about 69% of pretax adjusted profit, and the report flags that Japan's premium side is pressured by limited-pay-to-paid-up conversion and reinsurance; if the yen weakens it further erodes the dollar statements. This is a constraint, not a booster.

  All four must hold "simultaneously" to reach fivefold, and they even contradict one another (wanting multiple expansion while facing multiple-compression risk, wanting high growth while sitting on a single-digit base). Conclusion: fivefold in ten years is unrealistic—this is a name that the Baillie Gifford LTGG paradigm simply does not fit.

  Now the other half of Baillie Gifford's question—"what expectations does today's price imply." The answer: modest, conservative-leaning expectations, with no growth premium at all. The report's intrinsic-value ranges are conservative $80–95, fair $100–120, and optimistic $130–150, with the current $117.86 falling in the "upper half of the fair range," and on that basis it sets the rating at "Watch." The report's bottom-up estimated annualized returns are also only conservative 2%–4%, neutral 5%–7%, and optimistic 7%–9% (dividends included). In other words, the market prices Aflac as "a good company of steady-state compounding," not "a growth stock that will explode"—it gives no growth discount, so there is almost no explosive upside from "the market being wrong and it being severely undervalued."

  The cross-sectional comparison also supports this: the report shows Aflac's trailing P/E at about 13.4–13.5x and P/B about 2.0x, while Globe Life is about 10.8x P/E and Prudential about 10.7x P/E / 1.13x P/B—there are cheaper names among peers, and the market's willingness to give Aflac a slight premium is because its Japan franchise and capital allocation are superior, but "most of this advantage is now reflected in the price."

  In one line: the four conditions a fivefold gain requires—high growth, multiple expansion, efficient buybacks, and Japan tailwinds all holding at once—cannot be assembled in reality; and today's price already implies "fair-to-slightly-expensive mature cash cow" expectations with no growth premium—there is neither a fundamental engine for fivefold nor an undervaluation cushion, which is the arithmetic reason it is destined to be "Watch" rather than "heavy growth position."

  Jun 11, 2026
• QWhy hasn't the market realized all this yet? Does it not understand it, look down on it, or fail to look far enough? What would become the "narrative inflection point"?3/10

  A

  Conclusion: this Baillie Gifford question must be answered in reverse for Aflac—the market has not "failed to realize" a buried growth story; on the contrary, it already understands and prices this company quite fully: it is not that the market fails to understand, looks down on it, or fails to look far, but that it "sees clearly, and therefore assigns a fair-to-slightly-expensive mature-cash-cow valuation." Where a real perception gap exists is instead that "a static low P/E easily misleads people into thinking it is cheap." The so-called "narrative inflection point" is more likely a downward one—re-rating it from "steady-state compounding" to "weaker growth or higher risk"—rather than an upward ignition.

  First, the case that "the market basically gets it, with no undervalued growth narrative." The evidence is that the valuation already reflects its strengths: the report shows Aflac's trailing P/E at about 13.4–13.5x, P/B about 2.0x, and P/S about 3.39x; peers Globe Life about 10.8x P/E, Prudential about 10.7x P/E / 1.13x P/B, and MetLife about 16.3x P/E. The market is willing to give Aflac a revenue multiple and book multiple above most peers, and the report's explanation is precisely "because its Japan franchise and capital allocation are superior; but most of this advantage is now reflected in the price." A name the market "looks down on / fails to understand" would not enjoy a peer premium—Aflac enjoys a premium, showing it is understood, even slightly sought after. The share price confirms the same: the current price of about $117 hugs the 52-week high of $119.81, with a considerable year-to-date gain, hardly a stock the market has neglected.

  So how do Baillie Gifford's three sub-questions map on?

  "Fails to understand"? Only one part holds locally—accounting complexity, but it points toward "easily seeing it as cheap" rather than "seeing it as expensive." The report repeatedly flags that insurers' GAAP profit is distorted by investment volatility and currency: 2025 GAAP net income of $3.646 billion and a trailing GAAP P/E of about 13.47x, but switching to the $7.49 adjusted EPS that is closer to operating reality, it is actually about 15.7x. The real perception gap is that those looking only at a static low P/E misjudge it as "inherently cheap," when it is in fact merely fair-to-slightly-expensive. This is a perception gap that leads people to overstate its cheapness, not one that ignites upside.

  "Looks down on it"? Does not hold—it carries a valuation premium over peers, hardly disdained.

  "Fails to look far"? This is precisely the key, but its direction is negative for the growth thesis. The market looks far enough, and precisely sees that its organic growth is only low-to-mid single-digit (adjusted EPS four-year CAGR about 6.6%, book value excluding FX compounding only about 3.1%), that Japan is highly concentrated (about 53% of revenue, about 69% of pretax profit), and that buybacks lose marginal efficiency at high levels—which is why it does not give it a growth stock's high multiple. In other words, after "looking far," the market reaches the same conclusion as the report: this is a steady-state asset of good company, bad price, rated "Watch."

  Now the other half Baillie Gifford wants—"what would become the narrative inflection point." Honestly, for Aflac the most likely inflection is downward, rather than a re-rating into a growth stock:

  Downward inflection (listed in the report as overturning/re-rating signals, more realistic): Japan's trailing 12-month premium persistency clearly falling below the low-90% range, or Japan's pretax margin falling significantly below 30%; adjusted ROE excluding currency remeasurement dropping below 13% over the long run; the investment portfolio suffering worse-than-expected credit losses or private-placement-bond valuation disputes; U.S. supplemental insurance being significantly eroded by large medical insurers' bundling; or the June 2025 cybersecurity incident involving about 22.65 million people evolving into material regulatory fines/litigation. If any materializes, the market could knock the valuation back to 1.3–1.5x adjusted book or 10–12x adjusted EPS, corresponding to a share price of $65–80 (about 32%–45% below the current price).

  A theoretical upward inflection (harder to trigger): Japan growth re-accelerating with rising margins, currency providing a sustained tailwind, and the valuation multiple expanding further—but the report judges these are better suited to explaining "how much a good company could be worth" than "why to buy now," and they require multiple conditions to hold at once, a low probability.

  In one line: applying Baillie Gifford's "why hasn't the market realized" verbatim to Aflac goes astray—the market has not ignored it but understands it as a "fair-to-slightly-expensive mature cash cow" and prices it accordingly; the only perception gap is that a static low P/E easily deceives by making it look cheap, while the real narrative inflection is more likely a downward re-rating from deterioration in Japan/capital/valuation, rather than the discovery of undervalued growth. This is fully consistent with the report's conclusion of "Watch, good company bad price, wait for a better entry."

  Jun 11, 2026